Interleukin-12: Potential clinical applications in the treatment and prevention of infectious diseases

Drugs

Volumn 52, Issue SUPPL. 2, 1996, Pages 18-26

  Gately, Maurice K ^a   Mulqueen, Michael J ^b  

^a HOFFMANN LA ROCHE INC   (United States)

^b ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CYTOKINE; GAMMA INTERFERON; GANCICLOVIR; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 12; STIBOGLUCONATE SODIUM;

ANTIBODY PRODUCTION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOLYSIS; HELPER CELL; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; INFECTION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MONONUCLEAR CELL; MYCOBACTERIOSIS; MYCOSIS; NATURAL KILLER CELL; NONHUMAN; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PROTOZOAL INFECTION; SUBCUTANEOUS DRUG ADMINISTRATION; VIRUS INFECTION;

CORYNEBACTERINEAE; FUNGI; HUMAN IMMUNODEFICIENCY VIRUS; PROTOZOA;

EID: 0029824575     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199600522-00005     Document Type: Conference Paper

References (49)

1. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1944; 84: 4008-27
2. Brunda MJ, Gately MK. Interleukin-12: potential role in cancer therapy. In: DeVita Jr VT, Hellman S, Rosenberg SA, editors. Important advances in oncology 1995. Philadelphia: J.B. Lippincott, 1995: 3-18
3. Gubler U, Chua AO, Schoenhaut DS, et al. Coexpression of two distinct genes is required to generate secreted, bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA 1991; 88: 4143-7
4. Wolf SF, Temple PA, Kobayashi M, et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 1991; 146: 3074-81
5. Sieburth D, Jabs EW, Warrington JA, et al. Assignment of NKSF/IL 12, a unique cytokine composed of two unrelated subunits, to chromosomes 3 and 5. Genomics 1992; 14: 59-62
6. Naume B, Gately MK, Desai BB, et al. Synergistic effects of interleukin 4 and interleukin 12 on NK cell proliferation. Cytokine 1993; 5: 38-46
7. Desai BB, Quinn PM, Wolitzky AG, et al. IL-12 receptor. II. Distribution and regulation oF recepTor expression. J Immunol 1992; 148: 3125-32
8. Chua AO, Chizzonite R, Desai BB, et al. Expression cloning of a human IL-12 receptor component: a new member of the cytokine receptor superfamily with strong homology to gp130. J Immunol 1994; 153: 128-36
9. Presky DH, Gubler U, Chizzonite RA, et al. IL-12 receptors and receptor antagonists. Res Immunol. In press
10. Scott P. IL-12: initiation cytokine for cell-mediated immunity. Science 1993; 260: 496-7
11. Manetti R, Parronchi P, Giudizi MG, et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993; 177: 1199-204
12. H1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260: 547-9
13. Murphy EE, Terres G, Macatonia SE, et al. B7 and interleukin 12 cooperate for proliferation and interferon γ production by mouse T helper clones that are unresponsive to B7 costimulation. J Exp Med 1994; 180: 223-31
14. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J Exp Med 1989; 170: 827-45
15. Chan SH, Perussia B, Gupta JW, et al. Induction of interferon γ production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med 1991; 173: 869-79
16. Gazzinelli RT, Heiny S, Wynn TA, et al. Interleukin 12 is required for the T-lymphocyte-independent induction of interferon γ by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc Natl Acad Sci USA 1993; 90: 6115-9
17. Heinzel FP, Schoenhaut DS, Rerko RM, et al. Recombinant interleukin 12 cures mice infected with Leishmania major: J Exp Med 1993; 177: 1505-9
18. Gazzinelli RT, Giese NA, Morse III HC. In vivo treatment with interleukin 12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS). J Exp Med 1994; 180: 2199-208
19. Gately MK, Wolitzky AG, Quinn PM, et al. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol 1992; 143: 127-42
20. Gately MK, Warrier RR, Honasoge S, et al. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. Int Immunol 1994; 6: 157-67
21. Mehrotra PT, Wu D, Crim JA, et al. Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. J Immunol 1993; 151: 2444-52
22. Gately MK, Desai BB, Wolitzky AG, et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 1991; 147: 874-82
23. Jelinek DF, Braaten JK, Role of IL-12 in human B lymphocyte proliferation and differentiation. J Immunol 1995; 154: 1606-13
24. Germann T, Bongartz M, Dlugonska H, et al. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur J Immunol 1995; 25: 823-9
25. Sypek JP, Chung CL, Mayor SEH, et al. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med 1993; 177: 1797-802
26. Nabors GS, Afonso LCC, Farrell JP, et al. Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and Pcntostam. Proc Natl Acad Sci USA 1995; 92: 3142-6
27. Afonso LCC, Scharton TM, Vieira LQ, et al. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994; 263: 235-7
28. Gazzinelli R, Wysocka M, Hayashi S, et al. Parasite-induced IL-12 stimulates early IFN-γ synthesis and resistance during acute infection with Toxoplasma gondii. J Immunol 1994; 153: 2533-43
29. Cooper AM, Roberts AD, Rhoades ER, et al. The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology 1995; 84: 423-32
30. Zhou P, Sieve MC, Bennett J, et al. IL-12 prevents mortality in mice infected with Histoplasma capsulatum through induction of IFN-γ. J Immunol 1995; 155: 785-95
31. Romani L, Mencacci A, Tonnetti L, et al. IL-12 is both required and prognostic in vivo for T helper type 1 differentiation in murine candidiasis. J Immunol 1994; 153: 5167-75
32. Zhang M, Gately MK, Wang E, et al. Interleukin 12 at the site of disease in tuberculosis. J Clin Invest 1994; 93: 1733-9
33. Orange JS, Wolf SF, Biron CA. Effects of IL-12 on the response and susceptibility to experimental vital infections. J Immunol 1994; 152: 1253-64
34. Orange JS, Salazar-Mather TP, Opal SM, et al. Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids. J Exp Med 1995; 181: 901-14
35. Coutelier J-P, van Broeck J, Wolf SF. Interleukin-12 gene expression after viral infection in the mouse. J Virol 1995; 69: 1955-8
36. Clerici M, Shearer GM. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today 1994; 15: 575-81
37. Chehimi J, Starr SE, Frank I, et al. Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J Exp Med 1994; 179: 1361-6
38. Chehimi J, Starr SE, Frank I, et al. Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients. J Exp Med 1992; 175: 789-96
39. Clerici M, Lucey DR, Berzofsky JA, et al. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 1993; 262: 1721-4
40. Clerici M, Sarin A, Coffman RL, et al. Type 1/type 2 cytokine modulation of T-cell programmed cell death as a model for human immunodeficiency virus pathogenesis. Proc Natl Acad Sci USA 1994; 91: 11811-5
41. 2 stimulatory cytokines interleukin-12 and interleukin-4 on human immunodeficiency virus replication. Blood 1995; 85: 2114-23
42. Gately MK, Gubler U, Brunda MJ, et al. Interleukin-12: a cytokine with therapeutic potential in oncology and infectious diseases. Therapeutic Immunol 1994; 1: 187-96
43. Bree AG, Schlerman FJ, Kaviani MD, et al. Multiple effects on peripheral hematology following administration of recombinant human interleukin 12 to nonhuman primates. Biochem Biophys Res Comm 1994; 204: 1150-7
44. Sarmiento UM, Riley JH, Knaack PA, et al. Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Saimiri sciureus). Lab Invest 1994; 71: 862-73
45. Trembleau S, Penna G, Bosi E, et al. Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. J Exp Med 1995; 181: 817-21
46. Germann T, Szeliga J, Hess H, et al. Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice. Proc Natl Acad Sci USA 1995; 92: 4823-7
47. Ozmen L, Pericin M, Hakimi J, et al. Interleukin 12, interferon γ, and tumor necrosis factor a are the key cytokines of the generalized Shwartzman reaction. J Exp Med 1994; 180: 907-15
48. Wysocka M, Kubin M, Vieira LQ, et al. Interleukin-12 is required for interferon-γ production and lethality in lipopolysaccharide-induced shock in mice. Eur J Immunol 1995; 25: 672-6
49. Nadeau RR, Ostrowski C, Ni-Wu G, et al. Pharmacokinetics and pharmacodynamics of recombinant human interleukin-12 in male rhesus monkeys. J Pharmacol ExpTher 1995; 274: 78-83